Differential regulation of pericyte function by the CXC receptor 3

Wound Repair and Regeneration

Volumn 23, Issue 6, 2015, Pages 785-796

  Bodnar, Richard J ^a   Wells, Alan ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MITOGEN ACTIVATED PROTEIN KINASE 14; ANGIOGENIC FACTOR; CXCR3 PROTEIN, HUMAN;

ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RETINA; BLOOD VESSEL; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CHEMOTAXIS; CYTOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; WOUND HEALING;

ANGIOGENESIS INDUCING AGENTS; BLOOD VESSELS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOTAXIS; HUMANS; PERICYTES; PHOSPHORYLATION; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 84948443638     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12346     Document Type: Article

References (42)

1. von Tell D, Armulik A, Betsholtz C., Pericytes and vascular stability. Exp Cell Res 2006; 312: 623-9.
2. Allt G, Lawrenson JG., Pericytes: cell biology and pathology. Cells Tissues Organs 2001; 169: 1-11.
3. Peppiatt CM, Howarth C, Mobbs P, Attwell D., Bidirectional control of CNS capillary diameter by pericytes. Nature 2006; 443: 700-4.
4. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, et al., Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001; 153: 543-53.
5. Armulik A, Abramsson A, Betsholtz C., Endothelial/pericyte interactions. Circ Res 2005; 97: 512-23.
6. Farrington-Rock C, Crofts NJ, Doherty MJ, Ashton BA, Griffin-Jones C, Canfield AE., Chondrogenic and adipogenic potential of microvascular pericytes. Circulation 2004; 110: 2226-32.
7. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al., A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-13.
8. Dulmovits BM, Herman IM., Microvascular remodeling and wound healing: a role for pericytes. Int J Biochem Cell Biol 2012; 44: 1800-12.
9. Mills SJ, Cowin AJ, Kaur P., Pericytes, mesenchymal stem cells and the wound healing process. Cells 2013; 2: 621-34.
10. Tu Z, Li Y, Smith DS, Sheibani N, Huang S, Kern T, et al., Retinal pericytes inhibit activated T cell proliferation. Invest Ophthalmol Vis Sci 2011; 52: 9005-10.
11. Morikawa S, Ezaki T., Phenotypic changes and possible angiogenic roles of pericytes during wound healing in the mouse skin. Histol Histopathol 2011; 26: 979-95.
12. Juniantito V, Izawa T, Yuasa T, Ichikawa C, Yamamoto E, Kuwamura M, et al., Immunophenotypical analyses of myofibroblasts in rat excisional wound healing: possible transdifferentiation of blood vessel pericytes and perifollicular dermal sheath cells into myofibroblasts. Histol Histopathol 2012; 27: 515-27.
13. Betsholtz C, Lindblom P, Gerhardt H., Role of pericytes in vascular morphogenesis. EXS 2005: 115-25.
14. Bodnar RJ, Rodgers ME, Chen WC, Wells A., Pericyte regulation of vascular remodeling through the CXC receptor 3. Arterioscler Thromb Vasc Biol 2013; 33: 2818-29.
15. Bodnar RJ, Yates CC, Rodgers ME, Du X, Wells A., IP-10 induces dissociation of newly formed blood vessels. J Cell Sci 2009; 122 (Pt 12): 2064-77.
16. Yates CC, Whaley D, Kulasekeran P, Hancock WW, Lu B, Bodnar R, et al., Delayed and deficient dermal maturation in mice lacking the CXCR3 ELR-negative CXC chemokine receptor. Am J Pathol 2007; 171: 484-95.
17. Satish L, Yager D, Wells A., Glu-Leu-Arg-negative CXC chemokine interferon gamma inducible protein-9 as a mediator of epidermal-dermal communication during wound repair.[see comment]. J Invest Dermatol 2003; 120: 1110-7.
18. Yates CC, Whaley D, Hooda S, Hebda PA, Bodnar RJ, Wells A., Delayed reepithelialization and basement membrane regeneration after wounding in mice lacking CXCR3. Wound Repair Regen 2009; 17: 34-41.
19. Shiraha H, Glading A, Gupta K, Wells A., IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal growth factor receptor-mediated calpain activity. J Cell Biol 1999; 146: 243-54.
20. Bodnar RJ, Yates CC, Wells A., IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res 2006; 98: 617-25.
21. Huen AC, Wells A., The Beginning of the End: CXCR3 Signaling in Late-Stage Wound Healing. Adv Wound Care (New Rochelle) 2012; 1: 244-8.
22. Werner S, Grose R., Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83: 835-70.
23. Groom JR, Luster AD., CXCR3 in T cell function. Exp Cell Res 2011; 317: 620-31.
24. Hodge DL, Schill WB, Wang JM, Blanca I, Reynolds DA, Ortaldo JR, et al., IL-2 and IL-12 alter NK cell responsiveness to IFN-gamma-inducible protein 10 by down-regulating CXCR3 expression. J Immunol 2002; 168: 6090-8.
25. Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, et al., Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother 2007; 30: 417-24.
26. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al., An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197: 1537-49.
27. Bonacchi A, Romagnani P, Romanelli RG, Efsen E, Annunziato F, Lasagni L, et al., Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001; 276: 9945-54.
28. Crisan M, Deasy B, Gavina M, Zheng B, Huard J, Lazzari L, et al., Purification and long-term culture of multipotent progenitor cells affiliated with the walls of human blood vessels: myoendothelial cells and pericytes. Methods Cell Biol 2008; 86: 295-309.
29. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, et al., Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129-34.
30. Datta D, Banerjee P, Gasser M, Waaga-Gasser AM, Pal S., CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem 2010; 285: 36842-8.
31. Satish L, Blair HC, Glading A, Wells A., Interferon-inducible protein 9 (CXCL11)-induced cell motility in keratinocytes requires calcium flux-dependent activation of mu-calpain. Mol Cell Biol 2005; 25: 1922-41.
32. Petrai I, Romboutsa K, Lasagni L, Annunziato F, Cosmi L, Romanelli RG, et al., Activation of p38MAPK mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol 2008; 40: 1764-74.
33. Kouroumalis A, Nibbs RJ, Aptel H, Wright KL, Kolios G, Ward SG., The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol 2005; 175: 5403-11.
34. Trotta T, Costantini S, Colonna G., Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design. Mol Immunol 2009; 47: 332-9.
35. Xanthou G, Williams TJ, Pease JE., Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 2003; 33: 2927-36.
36. Shiraha H, Glading A, Chou J, Jia Z, Wells A., Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. Mol Cell Biol 2002; 22: 2716-27.
37. Wang X, Yue TL, Ohlstein EH, Sung CP, Feuerstein GZ., Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J Biol Chem 1996; 271: 24286-93.
38. Hedges JC, Dechert MA, Yamboliev IA, Martin JL, Hickey E, Weber LA, et al., A role for p38(MAPK)/HSP27 pathway in smooth muscle cell migration. J Biol Chem 1999; 274: 24211-9.
39. Chen S, Qiong Y, Gardner DG., A role for p38 mitogen-activated protein kinase and c-myc in endothelin-dependent rat aortic smooth muscle cell proliferation. Hypertension 2006; 47: 252-8.
40. Yates C, Rodgers M, Jaynes J, Wells A, Bodnar R, Turner T., An IP-10 derived peptide inhibits angiogenesis. PLoS One 2012; 7: e40812.
41. Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, et al., Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 2011; 117: 480-8.
42. Kurachi M, Kurachi J, Suenaga F, Tsukui T, Abe J, Ueha S, et al., Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med 2011; 208: 1605-20.